The Apollo Symposium on Pulmonary Interventions and Respiratory Excellence (ASPIRE) 2025 was recently held in Hyderabad, Telangana. The event brought together pulmonologists, rheumatologists, and healthcare professionals to discuss recent advancements in the diagnosis and management of Interstitial Lung Disease (ILD), a condition that affects an estimated 4-8 lakh people in India.
The symposium focused on bronchoscopic techniques, high-resolution imaging, and biomarker-driven diagnostics that are improving ILD detection. Experts also examined new pharmacological treatments, including antifibrotic drugs and biologics, which are shaping ILD management in India.
The event featured participation from leading international and national medical professionals, including experts from the University of Washington Medical Center, University of Cincinnati, and Baylor College of Medicine, among others.
The Apollo Hospitals Pulmonology Department organized the event, led by Dr. Sowmya Parimi, Dr. Vijay Kumar Chennamsetty, and other committee members. The symposium covered topics such as AI-driven diagnostics, cryobiopsy for tissue acquisition, pulmonary rehabilitation, lung transplantation, and remote monitoring for ILD patients.
Apollo Hospitals’ CEO, Mr. V Tejesvi Rao, highlighted the importance of integrating cutting-edge technology in respiratory care, while Dr. Ravindra Babu, Director Medical Services, emphasized the need for a collaborative approach to diagnose and manage ILD. The event served as a crucial knowledge-sharing platform, fostering collaboration among specialists to advance data-driven ILD diagnosis and targeted therapeutic interventions.
ASPIRE 2025 marked an important step in improving ILD management across India, with Apollo Hospitals committed to pioneering evidence-based and technology-driven respiratory care. The event reflects the hospital’s dedication to providing the best available care to patients and contributing to the advancement of medical knowledge.